Earnings History Data for G1 Therapeutics, Inc. (GTHX) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

G1 Therapeutics, Inc.

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel, small-molecule therapies which address significant unmet needs in the treatment of cancer. The company's product pipeline consists of CDK4/6, Trilaciclib (G1T28), G1T38 and G1T48. G1 Therapeutics, Inc. is based in Research Triangle Park, NC.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
08-08-2024	PM		GTHX	G1 Therapeutics, Inc.	222.20	-0.10	-0.17	0.14	G1 Therapeutics GAAP EPS of -$0.10 beats by $0.07, revenue of $16.55M beats by $0.52M [8/8/2024 6:31 AM]	7.09	0.03 (0.42%)	7.06	0.0 (0.00%)	1.08 - 7.10	11,311,246	4,430,000	412,313
G1 Therapeutics Q2 2024 Earnings Preview [8/7/2024 11:17 AM] G1 Therapeutics surges on merger deal with Pharmacosmos [8/7/2024 7:36 AM] G1 Therapeutics GAAP EPS of -$0.10 beats by $0.07, revenue of $16.55M beats by $0.52M [8/8/2024 6:31 AM]
01-05-2024	PM		GTHX	G1 Therapeutics, Inc.	194.18	-0.20	-0.19	-0.53	G1 Therapeutics reports mixed Q1 results; reaffirms FY24 outlook [5/1/2024 6:35 AM]	4.14	0.37 (9.95%)	3.58	-0.19 (-5.04%)	1.08 - 5.00	915,440	550,000	45,452
G1 Therapeutics and Pepper Bio sign license agreement for lerociclib [5/1/2024 8:30 AM] G1 Therapeutics reports mixed Q1 results; reaffirms FY24 outlook [5/1/2024 6:35 AM] G1 Therapeutics Q1 2024 Earnings Preview [4/30/2024 11:54 AM]
28-02-2024	PM		GTHX	G1 Therapeutics	115.00	-0.21	-0.27	0.00	G1 Therapeutics GAAP EPS of -$0.21 beats by $0.07, revenue of $14.9M beats by $1.87M [2/28/2024 6:32 AM]	3.33	0.93 (38.75%)	2.56	0.16 (6.67%)	1.08 - 5.00	4,809,513	2,340,000	110,553
G1 Therapeutics Q4 2023 Earnings Preview [2/27/2024 5:35 PM] G1 Therapeutics GAAP EPS of -$0.21 beats by $0.07, revenue of $14.9M beats by $1.87M [2/28/2024 6:32 AM]
01-11-2023	PM		GTHX	G1 Therapeutics, Inc.	81.76	-0.35	-0.31	-0.59	G1 Therapeutics GAAP EPS of -$0.35 misses by $0.02, revenue of $12.3M misses by $1.93M [11/1/2023 6:35 AM]	1.34	-0.31 (-18.79%)	1.38	-0.27 (-16.36%)	1.08 - 11.25	838,803	810,000	146,204
G1 Therapeutics Q3 2023 Earnings Preview [10/31/2023 2:00 PM] G1 Therapeutics GAAP EPS of -$0.35 misses by $0.02, revenue of $12.3M misses by $1.93M [11/1/2023 6:35 AM]
02-08-2023	PM		GTHX	G1 Therapeutics, Inc.	123.99	0.14	-0.17	-0.92	G1 Therapeutics GAAP EPS of $0.14 beats by $0.36, revenue of $42.39M beats by $13.48M [8/2/2023 6:34 AM]	2.15	-0.04 (-1.83%)	2.33	0.14 (6.39%)	2.11 - 17.49	4,950,919	1,210,000	341,136
G1 Therapeutics Q2 2023 Earnings Preview [8/1/2023 1:21 PM] G1 Therapeutics GAAP EPS of $0.14 beats by $0.36, revenue of $42.39M beats by $13.48M [8/2/2023 6:34 AM]
03-05-2023	PM	6:30 AM ET (May 3)	GTHX	G1 Therapeutics, Inc.	159.11	-0.53	-0.64	-1.15	G1 Therapeutics GAAP EPS of -$0.53 beats by $0.11, revenue of $12.9M beats by $1.53M [5/3/2023 6:34 AM]	2.99	0.02 (0.67%)	3.00	0.03 (1.01%)	2.38 - 17.49	1,890,810	740,000	31,019
G1 Therapeutics GAAP EPS of -$0.53 beats by $0.11, revenue of $12.9M beats by $1.53M [5/3/2023 6:34 AM]
01-03-2023	PM	6:30 AM ET (Mar 1)	GTHX	G1 Therapeutics, Inc.	190.81	-0.73	-0.85	-0.94	G1 Therapeutics GAAP EPS of -$0.73 beats by $0.11, revenue of $10.25M beats by $0.59M [3/1/2023 6:32 AM]	3.69	0.07 (2.07%)	3.73	0.11 (3.04%)	3.20 - 17.49	1,881,589	1,680,000	29,162
G1 Therapeutics Q4 2022 Earnings Preview [2/28/2023 1:04 PM] G1 Therapeutics GAAP EPS of -$0.73 beats by $0.11, revenue of $10.25M beats by $0.59M [3/1/2023 6:32 AM]
02-11-2022	PM	6:30 AM ET (Nov 2)	GTHX	G1 Therapeutics, Inc.	455.68	-0.59	-0.64	1.00	G1 Therapeutics GAAP EPS of -$0.59 beats by $0.04, revenue of $23.6M beats by $0.33M [11/2/2022 6:36 AM]	8.21	-2.71 (-24.79%)	9.99	-0.92 (-8.43%)	3.84 - 17.49	4,344,078	550,000	35,243
G1 Therapeutics GAAP EPS of -$0.59 beats by $0.04, revenue of $23.6M beats by $0.33M [11/2/2022 6:36 AM] G1 Therapeutics rises as trilaciclib potentially reduces adverse events linked with Trodelvy [11/2/2022 7:14 AM] G1 Therapeutics Provides Third Quarter 2022 Financial Results and Operational Highlights [Nov-02-22 06:30AM] Initial Results from Phase 2 Trial Demonstrate Potential of Trilaciclib to Reduce Adverse Events Related to an Antibody Drug Conjugate (ADC) [Nov-02-22 06:28AM] G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Nov-01-22 05:40PM]
03-08-2022	PM	6:30 AM ET (Aug 3)	GTHX	G1 Therapeutics, Inc.	349.76	-0.92	-1.04	-0.94	G1 Therapeutics GAAP EPS of -$0.92 beats by $0.10, revenue of $10.57M beats by $1.7M [8/3/2022 6:34 AM]	8.70	0.40 (4.82%)	8.61	0.31 (3.73%)	3.84 - 17.23	2,406,015	730,000	6,733
G1 Therapeutics Q2 2022 Earnings Preview [8/2/2022 2:05 PM] G1 Therapeutics GAAP EPS of -$0.92 beats by $0.10, revenue of $10.57M beats by $1.7M [8/3/2022 6:34 AM] G1 Therapeutics Provides Second Quarter 2022 Financial Results and Operational Highlights [Aug-03-22 06:30AM]
04-05-2022	PM	6:30 AM ET (May 4)	GTHX	G1 Therapeutics	220.00	-1.15	-0.99	0.00	G1 Therapeutics GAAP EPS of -$1.15 misses by $0.17, revenue of $6.9M beats by $0.78M [5/4/2022 6:32 AM]	5.46	0.0 (0.00%)	5.46	-0.01 (-0.18%)	4.91 - 24.12	785,465	650,000	16,139
G1 Therapeutics Q1 2022 Earnings Preview [5/3/2022 11:54 AM] G1 Therapeutics grants stock options to employees [5/3/2022 6:13 AM] G1 Therapeutics GAAP EPS of -$1.15 misses by $0.17, revenue of $6.9M beats by $0.78M [5/4/2022 6:32 AM] G1 Therapeutics stock falls 8% after Q1 loss widens due to higher costs [5/4/2022 11:41 AM] G1 Therapeutics Provides First Quarter 2022 Financial Results and Operational Highlights [May-04-22 06:30AM] G1 Therapeutics (GTHX) Reports Q1 Loss, Tops Revenue Estimates [May-04-22 07:45AM]
23-02-2022	PM	6:30 AM ET (Feb 23)	GTHX	G1 Therapeutics, Inc.	407.36	-0.94	-1.03	-0.67	G1 Therapeutics GAAP EPS of -$0.94 beats by $0.09, revenue of $5.79M beats by $0.07M [2/23/2022 6:34 AM]	9.78	0.14 (1.45%)	9.95	0.31 (3.22%)	8.04 - 26.69	670,795	670,000	10,605
G1 Therapeutics Q4 2021 Earnings Preview [2/22/2022 11:24 AM] G1 Therapeutics GAAP EPS of -$0.94 beats by $0.09, revenue of $5.79M beats by $0.07M [2/23/2022 6:34 AM] G1 Therapeutics Provides Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights [Feb-23-22 06:30AM] G1 Therapeutics (GTHX) Reports Q4 Loss, Tops Revenue Estimates [Feb-23-22 07:45AM] G1 Therapeutics, Inc. (GTHX) Q4 2021 Earnings Call Transcript [Feb-23-22 01:30PM]
03-11-2021	PM	0:00 AM ET (Nov 3)	GTHX	G1 Therapeutics, Inc.	642.42	-1.00	-1.03	-0.31	G1 Therapeutics EPS beats by $2.02, beats on revenue [11/3/2021 6:39 AM]	16.16	0.97 (6.39%)	14.50	-0.69 (-4.54%)	11.32 - 37.07	1,496,864	880,000	54,424
G1 Therapeutics EPS beats by $2.02, beats on revenue [11/3/2021 6:39 AM] G1 forges ahead with Cosela studies for breast cancer planned for this quarter [11/3/2021 12:00 PM] G1 Therapeutics Provides Third Quarter 2021 Financial Results and Operational Highlights [Nov-03-21 06:30AM] G1 Therapeutics (GTHX) Reports Q3 Loss, Tops Revenue Estimates [Nov-03-21 07:45AM] G1 Therapeutics, Inc (GTHX) Q3 2021 Earnings Call Transcript [Nov-03-21 04:01PM]
04-08-2021	AH	4:00 PM ET (Aug 4)	GTHX	G1 Therapeutics, Inc.	724.10	-0.94	-0.96	-0.83	G1 Therapeutics EPS beats by $0.04, beats on revenue [8/4/2021 4:09 PM]	16.14	-0.58 (-3.47%)	16.10	-0.62 (-3.71%)	10.81 - 37.07	1,059,379	720,000	36,965
G1 Therapeutics EPS beats by $0.04, beats on revenue [8/4/2021 4:09 PM] G1 Therapeutics Granted New Technology Add-On Payment (NTAP) for COSELA (Trilaciclib) by Centers for Medicare & Medicaid Services (CMS) [Aug-04-21 08:00AM] G1 Therapeutics Provides Second Quarter 2021 Financial Results and Operational Highlights [Aug-04-21 04:01PM] G1 THERAPEUTICS (GTHX) Reports Q2 Loss, Tops Revenue Estimates [Aug-04-21 05:15PM] G1 Therapeutics, inc (GTHX) Q2 2021 Earnings Call Transcript [Aug-05-21 03:31AM] Here's Why G1 THERAPEUTICS (GTHX) is Poised for a Turnaround After Losing 16.4% in 4 Weeks [Aug-05-21 10:00AM]
05-05-2021	AH	4:00 PM ET (May 5)	GTHX	G1 Therapeutics, Inc.	884.08	-0.65	-1.09	-0.82	G1 Therapeutics EPS beats by $0.42, beats on revenue [5/5/2021 4:05 PM]	19.57	-0.20 (-1.01%)	19.57	0.0 (0.00%)	10.81 - 37.07	2,010,974	860,000	23,800
G1 Therapeutics, Inc. to Host Earnings Call [May-05-21 02:45PM] G1 Therapeutics Provides First Quarter 2021 Financial Results and Operational Highlights [May-05-21 04:01PM] G1 THERAPEUTICS (GTHX) Reports Q1 Loss, Tops Revenue Estimates [May-05-21 06:20PM] G1 Therapeutics, Inc. (GTHX) Q1 2021 Earnings Call Transcript [May-06-21 04:30AM]
24-02-2021	AH	4:00 PM ET (Feb 24)	GTHX	G1 Therapeutics, Inc.	981.97	-0.67	-0.88	-0.94	G1 Therapeutics EPS beats by $0.23, beats on revenue [2/24/2021 4:28 PM]	22.45	-2.69 (-10.70%)	25.69	0.55 (2.19%)	8.80 - 37.07	2,723,822	2,671,563	23,256
G1 Therapeutics EPS beats by $0.23, beats on revenue [2/24/2021 4:28 PM] Recap: G1 Therapeutics Q4 Earnings [Feb-24-21 05:23PM] G1 Therapeutics Provides Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights [Feb-24-21 04:01PM] G1 Therapeutics, Inc. to Host Earnings Call [Feb-24-21 02:30PM]
04-11-2020	AH	4:00 PM ET (Nov 4)	GTHX	G1 Therapeutics, Inc.	426.14	-0.31	-0.25	-0.86	G1 Therapeutics EPS misses by $0.01, beats on revenue, FY20 guidance update [11/4/2020 4:16 PM]	12.08	0.18 (1.51%)	12.60	0.70 (5.88%)	8.80 - 31.38	1,021,751	940,679	4,286

05-08-2020	AH	4:00 PM ET (Aug 5)	GTHX	G1 Therapeutics, Inc.	553.61	-0.83	-0.82	-0.82	G1 Therapeutics EPS in-line, misses on revenue [8/5/2020 4:16 PM]	17.00	1.44 (9.22%)	16.70	1.13 (7.26%)	8.80 - 41.80	534,029	534,739	9,107

06-05-2020	AH		GTHX	G1 Therapeutics, Inc.	508.32	-0.82	-0.98	-0.64		0.0	0.0 (0.00%)	0.0	0.0 (0.00%)	0.0 - 0.0	0	0	0